{"name":"Allergopharma GmbH & Co. KG","slug":"allergopharma-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"Allergopharma GmbH & Co. KG is a specialized pharmaceutical company focused on the research, development, and commercialization of allergy treatments. The company has a strong portfolio of 17 drugs, with several in late-stage clinical trials and marketed products.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Grass pollen specific immunotherapy","genericName":"Grass pollen specific immunotherapy","slug":"grass-pollen-specific-immunotherapy","indication":"Grass pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"House dust mite Novo Helisen Depot","genericName":"House dust mite Novo Helisen Depot","slug":"house-dust-mite-novo-helisen-depot","indication":"House dust mite allergy (allergic rhinitis and/or allergic asthma)","status":"marketed"},{"name":"AL0704rP","genericName":"AL0704rP","slug":"al0704rp","indication":"Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design)","status":"phase_3"},{"name":"Allerslit forte","genericName":"Allerslit forte","slug":"allerslit-forte","indication":"Allergic rhinitis and/or allergic asthma caused by specific environmental allergens","status":"phase_3"},{"name":"Birch pollen allergoid","genericName":"Birch pollen allergoid","slug":"birch-pollen-allergoid","indication":"Birch pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"Grass pollen formulation","genericName":"Grass pollen formulation","slug":"grass-pollen-formulation","indication":"Grass pollen-induced allergic rhinitis","status":"phase_3"},{"name":"Recombinant birch pollen","genericName":"Recombinant birch pollen","slug":"recombinant-birch-pollen","indication":"Birch pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"Recombinant grass pollen","genericName":"Recombinant grass pollen","slug":"recombinant-grass-pollen","indication":"Grass pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"},{"name":"recombinant birch pollen allergen","genericName":"recombinant birch pollen allergen","slug":"recombinant-birch-pollen-allergen","indication":"Birch pollen-induced allergic rhinitis and/or allergic asthma","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"Acaroid","genericName":"Acaroid","slug":"acaroid","indication":"Other","status":"phase_3"},{"name":"Biological: AL0206st","genericName":"Biological: AL0206st","slug":"biological-al0206st","indication":"Other","status":"phase_2"},{"name":"wasp venom","genericName":"wasp venom","slug":"wasp-venom","indication":"Wasp venom allergy with systemic reactions (prevention of anaphylaxis)","status":"marketed"}]}],"pipeline":[{"name":"Grass pollen specific immunotherapy","genericName":"Grass pollen specific immunotherapy","slug":"grass-pollen-specific-immunotherapy","phase":"phase_3","mechanism":"Grass pollen specific immunotherapy desensitizes the immune system to grass pollen allergens by gradually introducing increasing doses to induce immune tolerance.","indications":["Grass pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"House dust mite Novo Helisen Depot","genericName":"House dust mite Novo Helisen Depot","slug":"house-dust-mite-novo-helisen-depot","phase":"marketed","mechanism":"House dust mite allergen extract that desensitizes the immune system through repeated subcutaneous administration to reduce allergic responses.","indications":["House dust mite allergy (allergic rhinitis and/or allergic asthma)"],"catalyst":""},{"name":"AL0704rP","genericName":"AL0704rP","slug":"al0704rp","phase":"phase_3","mechanism":"AL0704rP is an allergen immunotherapy designed to modulate immune tolerance to specific allergens through controlled exposure and immune desensitization.","indications":["Allergic rhinitis and/or allergic asthma (specific allergen to be determined by trial design)"],"catalyst":""},{"name":"Acaroid","genericName":"Acaroid","slug":"acaroid","phase":"phase_3","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Allerslit forte","genericName":"Allerslit forte","slug":"allerslit-forte","phase":"phase_3","mechanism":"Allerslit forte is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual exposure to increasing doses.","indications":["Allergic rhinitis and/or allergic asthma caused by specific environmental allergens"],"catalyst":""},{"name":"Biological: AL0206st","genericName":"Biological: AL0206st","slug":"biological-al0206st","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Birch pollen allergoid","genericName":"Birch pollen allergoid","slug":"birch-pollen-allergoid","phase":"phase_3","mechanism":"Birch pollen allergoid is a modified birch pollen extract that induces immune tolerance to birch pollen allergens through gradual desensitization.","indications":["Birch pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"Grass pollen formulation","genericName":"Grass pollen formulation","slug":"grass-pollen-formulation","phase":"phase_3","mechanism":"A grass pollen allergen extract that desensitizes the immune system to grass pollen allergens through repeated controlled exposure.","indications":["Grass pollen-induced allergic rhinitis","Grass pollen-induced allergic asthma"],"catalyst":""},{"name":"Recombinant birch pollen","genericName":"Recombinant birch pollen","slug":"recombinant-birch-pollen","phase":"phase_3","mechanism":"Recombinant birch pollen allergen extract desensitizes the immune system to birch pollen through repeated controlled exposure, reducing allergic responses.","indications":["Birch pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"Recombinant grass pollen","genericName":"Recombinant grass pollen","slug":"recombinant-grass-pollen","phase":"phase_3","mechanism":"Recombinant grass pollen allergen extract desensitizes the immune system to grass pollen by inducing immune tolerance through repeated controlled exposure.","indications":["Grass pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"recombinant birch pollen allergen","genericName":"recombinant birch pollen allergen","slug":"recombinant-birch-pollen-allergen","phase":"phase_3","mechanism":"Recombinant birch pollen allergen is used in allergen immunotherapy to desensitize the immune system to birch pollen by inducing tolerance through repeated controlled exposure to the allergen.","indications":["Birch pollen-induced allergic rhinitis and/or allergic asthma"],"catalyst":""},{"name":"wasp venom","genericName":"wasp venom","slug":"wasp-venom","phase":"marketed","mechanism":"Wasp venom contains allergenic proteins that are used in allergen immunotherapy to desensitize patients to wasp stings by inducing immune tolerance.","indications":["Wasp venom allergy with systemic reactions (prevention of anaphylaxis)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWlhZTF3WHcwOWE5dGxjak5uQXBDN3FGSm9SaXkxaG1NdjYxQllQUjFaYkRpMXYtLTdZaHc3Wlk5TV9WbTBxS3VxUjNUOFJ2bkNybDZEb0dTRC0xYzV3eE1nZk1QNV8zcXplU0VVNG85UzEyT3BzaExnajltQVVFd1FNX0Q2X2lCODlXSGhnY1JDcE0?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market - openPR.com","headline":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNWlR2eHlpU0RMT2N2NmRwZlktNEJIWlBnSEZVZ1J2TkFaWFdyYWMwN1FNSlpsQ1BzM0VuaUZVbEtwOVc5bU43Y0lBNkNnY2RDM055Z2h2bTJzM010QU5LZFFOd2JBNjRZMHlPV1Bld3paZ1BaREtNVlVsNGZ1Uk1xRFdoUGFmdEhMYXZXU2l1UmlMN0tnTHlWaWRCUFV2ZWtBSzVfYTNIU2xGVWkxeVVwQjhZT01taDZuWXlRRjNKUlZMRWNySTU5QnRnSFlPMnpzVDEzeHRlazR5OVhJV05GQnp5UFE?oc=5","date":"2025-10-02","type":"pipeline","source":"PharmiWeb.com","summary":"Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK - PharmiWeb.com","headline":"Allergy Treatment Global Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, ALK","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOc3ltQlRtbFJuUFlKc2NWSTdSZWdxYUhyU3Z6aTFmTTBBajBsRkM4bW9sdl9fQWp5NEdXMkJUTlpnb3QxNl9fT2hrS19XVFM2ZzZ2UEEtTjZ0aG54SnA4NE5OMVhNQl9uT1lGZ3dZMTV1UlREbzMzekNVS2s2TnBqZWlaYzJhd0p6WEctV2t4WXI0SjdmN0czdjdydXpIeWhKeURMdjlocGhtUHU5?oc=5","date":"2022-08-11","type":"pipeline","source":"European Medical Journal","summary":"Reconsider the Art of Allergen Immunotherapy - European Medical Journal","headline":"Reconsider the Art of Allergen Immunotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxORWMxd0hOSGQzSUhZQlE5MzNRZV9aVmtZQUFNNDduTFpYZXlmcWNzUldNN1NoVVNBYjhydy1iRWQ4X1VwSzlWNUgwVDJKNF9jSWx3MXlsUUZ5VXk4aTI0dTdjaUpWbjhLckMzZnBiU1Vvb0ZfeDVFSG9XeDZ3Und2elRrcWxoX2gyUzhjSnVkVQ?oc=5","date":"2020-11-03","type":"pipeline","source":"Dermatology Times","summary":"Biologics, small molecule drugs expand AD options - Dermatology Times","headline":"Biologics, small molecule drugs expand AD options","sentiment":"neutral"}],"patents":[],"drugCount":12,"phaseCounts":{"phase_3":9,"marketed":2,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}